Kids_First_Biospecimen_ID_DNA	Kids_First_Biospecimen_ID_RNA	gene_symbol	cancer_group	pathology_free_text_diagnosis	copy_number	MYCN_TPM	status	Match_ID
BS_0RBGK29M	BS_KC02E200	MYCN	Neuroblastoma	NA	3	47.21	gain	PASMIU_01_GMKF
BS_2FPVHEQS	BS_GR7694W1	MYCN	Neuroblastoma	NA	145	404.76	amplification	PAUUHY_01_GMKF
BS_3564XTTK	BS_3CSY3JTN	MYCN	Neuroblastoma	NA	647	375.71	amplification	PASNUI_01_GMKF
BS_3AKS23A0	BS_F2F7BXT5	MYCN	Neuroblastoma	NA	3	24.78	gain	PATLFX_01_GMKF
BS_4J8JK335	BS_H4TFY19Z	MYCN	Neuroblastoma	NA	5	96.4	amplification	PAUJEJ_01_GMKF
BS_4NPEMNAD	BS_DY88N5ZT	MYCN	Neuroblastoma	Metastatic secondary tumors;Neuroblastoma	100	83.29	amplification	PT_DFCZAG9T_7316-224_PBTA
BS_5BB8J64W	BS_T7MWWC0A	MYCN	Neuroblastoma	NA	3	26.39	gain	PAUPWN_01_GMKF
BS_64P50TAP	BS_CZMY8CVE	MYCN	Neuroblastoma	NA	3	42.78	gain	PATFIK_01_GMKF
BS_76SQJSHP	BS_BW9QBKEQ	MYCN	Neuroblastoma	NA	5	33.58	gain	PATXTF_01_GMKF
BS_7BJQNVK8	BS_EMBK3HHP	MYCN	Neuroblastoma	NA	3	17.84	gain	PAVINE_01_GMKF
BS_8XDZQKSD	BS_MPE34NYZ	MYCN	Neuroblastoma	MYCN amp	3	334.91	gain	PASWYR_01_GMKF
BS_9ZDR2H7D	BS_XZQE9FBM	MYCN	Neuroblastoma	NA	106	245.8	amplification	PASXSJ_01_GMKF
BS_A527Y2QF	BS_S4WH99C9	MYCN	Neuroblastoma	NA	18	213.48	amplification	PATZRF_01_GMKF
BS_A5AQFAFA	BS_QJ3XB7XZ	MYCN	Ganglioneuroblastoma	NA	3	27.01	gain	PATLKI_01_GMKF
BS_ACCE0MEA	BS_94ZKC2SR	MYCN	Neuroblastoma	NA	3	269.8	gain	PASPGB_01_GMKF
BS_AE718N55	BS_ZWRZRC4V	MYCN	Neuroblastoma	NA	3	44.21	gain	PASLTC_01_GMKF
BS_APY3G22J	BS_A70FPYSH	MYCN	Neuroblastoma	NA	3	30.4	gain	PASWEE_01_GMKF
BS_B2RYV4GG	BS_S32M2YTY	MYCN	Neuroblastoma	NA	3	20.41	gain	PATTHB_01_GMKF
BS_BF83XX7P	BS_NJSZSZX5	MYCN	Neuroblastoma	NA	3	15.73	gain	PATSCT_01_GMKF
BS_BTRGQHM4	BS_HHNQ3N2V	MYCN	Neuroblastoma	NA	3	21.94	gain	PAULZB_01_GMKF
BS_C2FYP4KW	BS_H9BW7Y9C	MYCN	Neuroblastoma	NA	4	23.53	gain	PAUUTW_01_GMKF
BS_CD6KRB1K	BS_GWN2F333	MYCN	Neuroblastoma	NA	3	25.93	gain	PASRRY_01_GMKF
BS_CWPHVM94	BS_48YZKWC2	MYCN	Neuroblastoma	NA	4	31.01	gain	PAUYJS_01_GMKF
BS_DGV11G69	BS_RZEEJETF	MYCN	Neuroblastoma	NA	3	19.49	gain	PASZTC_01_GMKF
BS_DWYR5CTE	BS_W5X4568N	MYCN	Neuroblastoma	NA	132	290.47	amplification	PASCWD_01_GMKF
BS_FAEHNS3Q	BS_4JVC08W2	MYCN	Neuroblastoma	NA	3	21.71	gain	PASUCU_01_GMKF
BS_FJP95JXF	BS_ZFJS669M	MYCN	Neuroblastoma	NA	3	311.07	gain	PAUJRW_01_GMKF
BS_GZG7GH62	BS_TT20NP68	MYCN	Neuroblastoma	NA	3	23.2	gain	PAUNST_01_GMKF
BS_HZKJMB0D	BS_YA56YE71	MYCN	Neuroblastoma	NA	29	74.25	amplification	PATWED_01_GMKF
BS_JV1GTZ1Q	BS_82Q78622	MYCN	Neuroblastoma	NA	3	30.16	gain	PAVGYW_01_GMKF
BS_KP0YNTAK	BS_1RT76ANT	MYCN	Neuroblastoma	Metastatic secondary tumors;Neuroblastoma	4	9.38	gain	PT_5SX0GRW1_7316-1927_PBTA
BS_NVJJJ7MT	BS_WKPG4MH1	MYCN	Neuroblastoma	NA	3	40.72	gain	PASNHY_01_GMKF
BS_P0BHM8S1	BS_CCV91DR0	MYCN	Neuroblastoma	NA	59	57.78	amplification	PAUMJN_01_GMKF
BS_QDRHQSPZ	BS_6WBAV14H	MYCN	Neuroblastoma	NA	3	313.7	gain	PASKIS_01_GMKF
BS_R13WNSAR	BS_GMH5C45K	MYCN	Neuroblastoma	NA	54	345.49	amplification	PASWXG_01_GMKF
BS_SMJRCVQB	BS_0D3SCV7P	MYCN	Neuroblastoma	NA	3	8.29	gain	PATXKN_01_GMKF
BS_SYSZCYYZ	BS_97SKFHM4	MYCN	Neuroblastoma	NA	222	171.07	amplification	PASCDX_01_GMKF
BS_T5BAS1JN	BS_8MYS5HP4	MYCN	Neuroblastoma	NA	68	241.34	amplification	PAUGJI_01_GMKF
BS_T9VPRPVA	BS_3KGHX57D	MYCN	Neuroblastoma	NA	3	19.69	gain	PASFXC_01_GMKF
BS_TS07B3TC	BS_5Z1QJPG6	MYCN	Neuroblastoma	NA	3	54.09	gain	PASRTR_01_GMKF
BS_V4VGG98Y	BS_EZRVK9ZQ	MYCN	Neuroblastoma	MYCN non-amp	3	29.28	gain	PASXHE_01_GMKF
BS_WBZBDN0A	BS_6YYC47K2	MYCN	Neuroblastoma	NA	4	36.01	gain	PAUEXM_01_GMKF
BS_WRZATZQF	BS_JFJYEHFM	MYCN	Neuroblastoma	NA	3	16.22	gain	PATLFF_01_GMKF
BS_X2D8S1HY	BS_8VPBB5C2	MYCN	Neuroblastoma	NA	3	38.35	gain	PASEWZ_01_GMKF
BS_ZED6T1CT	BS_896YFFGE	MYCN	Neuroblastoma	NA	30	75.36	amplification	PAUTFT_01_GMKF
TARGET-30-PAIFXV-01A-01D	TARGET-30-PAIFXV-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	3.38	gain	PAIFXV_01_TARGET
TARGET-30-PAIPGU-01A-01W	TARGET-30-PAIPGU-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	20.29	gain	PAIPGU_01_TARGET
TARGET-30-PAITCI-01A-01W	TARGET-30-PAITCI-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	20.11	loss	PAITCI_01_TARGET
TARGET-30-PAITEG-01A-01W	TARGET-30-PAITEG-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	1.41	neutral	PAITEG_01_TARGET
TARGET-30-PAIVHE-01A-01W	TARGET-30-PAIVHE-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	45.8	loss	PAIVHE_01_TARGET
TARGET-30-PAKYZS-01A-01W	TARGET-30-PAKYZS-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	10.09	neutral	PAKYZS_01_TARGET
TARGET-30-PALBFW-01A-01W	TARGET-30-PALBFW-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	25.2	neutral	PALBFW_01_TARGET
TARGET-30-PALCBW-01A-01W	TARGET-30-PALCBW-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	3.82	loss	PALCBW_01_TARGET
TARGET-30-PALETP-01A-01W	TARGET-30-PALETP-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	38.47	neutral	PALETP_01_TARGET
TARGET-30-PALEVG-01A-01W	TARGET-30-PALEVG-01A-01R	MYCN	Neuroblastoma	MYCN amp	44	841.17	amplification	PALEVG_01_TARGET
TARGET-30-PALIIN-01A-01W	TARGET-30-PALIIN-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	65.69	loss	PALIIN_01_TARGET
TARGET-30-PALTEG-01A-01W	TARGET-30-PALTEG-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	20.09	neutral	PALTEG_01_TARGET
TARGET-30-PALWVJ-01A-01W	TARGET-30-PALWVJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	10.08	neutral	PALWVJ_01_TARGET
TARGET-30-PALZZV-01A-01W	TARGET-30-PALZZV-01A-01R	MYCN	Neuroblastoma	MYCN amp	86	888.26	amplification	PALZZV_01_TARGET
TARGET-30-PAMMXF-01A-01W	TARGET-30-PAMMXF-01A-01R	MYCN	Neuroblastoma	MYCN amp	2	536	neutral	PAMMXF_01_TARGET
TARGET-30-PAMVRA-01A-01W	TARGET-30-PAMVRA-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	65.33	loss	PAMVRA_01_TARGET
TARGET-30-PAMYCE-01A-01W	TARGET-30-PAMYCE-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	26.63	loss	PAMYCE_01_TARGET
TARGET-30-PAMZGT-01A-01W	TARGET-30-PAMZGT-01A-01R	MYCN	Neuroblastoma	MYCN amp	23	238.17	amplification	PAMZGT_01_TARGET
TARGET-30-PAMZMG-01A-01W	TARGET-30-PAMZMG-01A-01R	MYCN	Neuroblastoma	MYCN amp	44	641.29	amplification	PAMZMG_01_TARGET
TARGET-30-PANBMJ-01A-01W	TARGET-30-PANBMJ-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	3.78	neutral	PANBMJ_01_TARGET
TARGET-30-PANBSP-01A-01W	TARGET-30-PANBSP-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	52.35	neutral	PANBSP_01_TARGET
TARGET-30-PANKFE-01A-01W	TARGET-30-PANKFE-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	4.74	neutral	PANKFE_01_TARGET
TARGET-30-PANLET-01A-01D	TARGET-30-PANLET-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	36.1	loss	PANLET_01_TARGET
TARGET-30-PANRHJ-01A-01W	TARGET-30-PANRHJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	25.28	neutral	PANRHJ_01_TARGET
TARGET-30-PANRVJ-01A-01D	TARGET-30-PANRVJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	30.22	loss	PANRVJ_01_TARGET
TARGET-30-PANSBN-01A-01D	TARGET-30-PANSBN-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	0.74	neutral	PANSBN_01_TARGET
TARGET-30-PANUIF-01A-01D	TARGET-30-PANUIF-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	14.77	gain	PANUIF_01_TARGET
TARGET-30-PANWRR-01A-01D	TARGET-30-PANWRR-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	47.51	neutral	PANWRR_01_TARGET
TARGET-30-PANXJL-01A-01D	TARGET-30-PANXJL-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	1.77	loss	PANXJL_01_TARGET
TARGET-30-PANYGR-01A-01W	TARGET-30-PANYGR-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	36.9	loss	PANYGR_01_TARGET
TARGET-30-PANZPV-01A-01W	TARGET-30-PANZPV-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	12.32	loss	PANZPV_01_TARGET
TARGET-30-PANZVU-01A-01W	TARGET-30-PANZVU-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	41.2	loss	PANZVU_01_TARGET
TARGET-30-PAPBGH-01A-01W	TARGET-30-PAPBGH-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	0.51	loss	PAPBGH_01_TARGET
TARGET-30-PAPBJE-01A-01D	TARGET-30-PAPBJE-01A-01R	MYCN	Neuroblastoma	MYCN amp	216	794.4	amplification	PAPBJE_01_TARGET
TARGET-30-PAPBZI-01A-01W	TARGET-30-PAPBZI-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	4	24.12	gain	PAPBZI_01_TARGET
TARGET-30-PAPCTS-01A-01D	TARGET-30-PAPCTS-01A-01R	MYCN	Neuroblastoma	MYCN amp	129	1730.92	amplification	PAPCTS_01_TARGET
TARGET-30-PAPEFE-01A-01W	TARGET-30-PAPEFE-01A-01R	MYCN	Neuroblastoma	MYCN amp	7	256.18	amplification	PAPEFE_01_TARGET
TARGET-30-PAPHPE-01A-01W	TARGET-30-PAPHPE-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	6.75	neutral	PAPHPE_01_TARGET
TARGET-30-PAPKWN-01A-01W	TARGET-30-PAPKWN-01A-01R	MYCN	Neuroblastoma	MYCN amp	13	53.77	amplification	PAPKWN_01_TARGET
TARGET-30-PAPKXS-01A-01D	TARGET-30-PAPKXS-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	156.12	gain	PAPKXS_01_TARGET
TARGET-30-PAPLSD-01A-01D	TARGET-30-PAPLSD-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	27.18	gain	PAPLSD_01_TARGET
TARGET-30-PAPTAN-01A-01D	TARGET-30-PAPTAN-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	17.55	neutral	PAPTAN_01_TARGET
TARGET-30-PAPTCR-01A-01D	TARGET-30-PAPTCR-01A-01R	MYCN	Neuroblastoma	NA	2	6.25	neutral	PAPTCR_01_TARGET
TARGET-30-PAPTFZ-01A-01D	TARGET-30-PAPTFZ-01A-01R	MYCN	Neuroblastoma	MYCN amp	125	963.04	amplification	PAPTFZ_01_TARGET
TARGET-30-PAPTLV-01A-01D	TARGET-30-PAPTLV-01A-01R	MYCN	Neuroblastoma	MYCN amp	24	287.38	amplification	PAPTLV_01_TARGET
TARGET-30-PAPUWY-01A-01D	TARGET-30-PAPUWY-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	54.03	loss	PAPUWY_01_TARGET
TARGET-30-PAPVFD-01A-01D	TARGET-30-PAPVFD-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	83.89	neutral	PAPVFD_01_TARGET
TARGET-30-PAPVRN-01A-01D	TARGET-30-PAPVRN-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	7.12	loss	PAPVRN_01_TARGET
TARGET-30-PAPVXS-01A-01D	TARGET-30-PAPVXS-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	41.63	neutral	PAPVXS_01_TARGET
TARGET-30-PAPZYZ-01A-01D	TARGET-30-PAPZYZ-01A-01R	MYCN	Neuroblastoma	MYCN amp	131	297.49	amplification	PAPZYZ_01_TARGET
TARGET-30-PARACS-01A-01D	TARGET-30-PARACS-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	41.99	neutral	PARACS_01_TARGET
TARGET-30-PARAMT-01A-01D	TARGET-30-PARAMT-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	3	84.91	neutral	PARAMT_01_TARGET
TARGET-30-PARBGP-01A-01D	TARGET-30-PARBGP-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	64.79	loss	PARBGP_01_TARGET
TARGET-30-PARDCK-01A-01D	TARGET-30-PARDCK-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	9.06	loss	PARDCK_01_TARGET
TARGET-30-PARDIW-01A-01D	TARGET-30-PARDIW-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	27.17	loss	PARDIW_01_TARGET
TARGET-30-PARFWB-01A-01D	TARGET-30-PARFWB-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	39.63	neutral	PARFWB_01_TARGET
TARGET-30-PARGKK-01A-01D	TARGET-30-PARGKK-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	37.51	neutral	PARGKK_01_TARGET
TARGET-30-PARKGJ-01A-01D	TARGET-30-PARKGJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	11.58	gain	PARKGJ_01_TARGET
TARGET-30-PARSBI-01A-01D	TARGET-30-PARSBI-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	14.69	loss	PARSBI_01_TARGET
TARGET-30-PARVLK-01A-01D	TARGET-30-PARVLK-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	13.46	loss	PARVLK_01_TARGET
TARGET-30-PARYNK-01A-01D	TARGET-30-PARYNK-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	6.28	neutral	PARYNK_01_TARGET
TARGET-30-PARZIP-01A-01D	TARGET-30-PARZIP-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	61.24	loss	PARZIP_01_TARGET
TARGET-30-PASEGA-01A-01D	TARGET-30-PASEGA-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	19.7	neutral	PASEGA_01_TARGET
TARGET-30-PASFGG-01A-01D	TARGET-30-PASFGG-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	22.7	neutral	PASFGG_01_TARGET
TARGET-30-PASGAP-01A-01D	TARGET-30-PASGAP-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	6.4	loss	PASGAP_01_TARGET
TARGET-30-PASGUT-01A-01D	TARGET-30-PASGUT-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	25.36	loss	PASGUT_01_TARGET
TARGET-30-PASMJG-01A-01D	TARGET-30-PASMJG-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	1.99	neutral	PASMJG_01_TARGET
TARGET-30-PASMNT-01A-01D	TARGET-30-PASMNT-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	53.58	neutral	PASMNT_01_TARGET
TARGET-30-PASNEF-01A-01D	TARGET-30-PASNEF-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	38.07	loss	PASNEF_01_TARGET
TARGET-30-PASNZU-01A-01D	TARGET-30-PASNZU-01A-01R	MYCN	Neuroblastoma	MYCN amp	152	1197.28	amplification	PASNZU_01_TARGET
TARGET-30-PASPER-01A-01D	TARGET-30-PASPER-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	16.46	neutral	PASPER_01_TARGET
TARGET-30-PASRFS-01A-01D	TARGET-30-PASRFS-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	51.69	neutral	PASRFS_01_TARGET
TARGET-30-PASSRN-01A-01D	TARGET-30-PASSRN-01A-01R	MYCN	Neuroblastoma	MYCN amp	522	836.66	amplification	PASSRN_01_TARGET
TARGET-30-PASSRS-01A-01D	TARGET-30-PASSRS-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	21.15	loss	PASSRS_01_TARGET
TARGET-30-PASTCN-01A-01D	TARGET-30-PASTCN-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	41.76	loss	PASTCN_01_TARGET
TARGET-30-PASTKC-01A-01D	TARGET-30-PASTKC-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	27.41	loss	PASTKC_01_TARGET
TARGET-30-PASUCB-01A-01D	TARGET-30-PASUCB-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	12.61	loss	PASUCB_01_TARGET
TARGET-30-PASUYG-01A-01D	TARGET-30-PASUYG-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	9.05	neutral	PASUYG_01_TARGET
TARGET-30-PASVRU-01A-01D	TARGET-30-PASVRU-01A-01R	MYCN	Neuroblastoma	MYCN amp	121	553.88	amplification	PASVRU_01_TARGET
TARGET-30-PASWFB-01A-01D	TARGET-30-PASWFB-01A-01R	MYCN	Neuroblastoma	MYCN amp	195	1168.07	amplification	PASWFB_01_TARGET
TARGET-30-PASWIJ-01A-01D	TARGET-30-PASWIJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	63.29	neutral	PASWIJ_01_TARGET
TARGET-30-PASWVY-01A-01D	TARGET-30-PASWVY-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	4	86.39	gain	PASWVY_01_TARGET
TARGET-30-PASWYR-01A-01D	TARGET-30-PASWYR-01A-01R	MYCN	Neuroblastoma	MYCN amp	138	1165.28	amplification	PASWYR_01_TARGET
TARGET-30-PASXGP-01A-01D	TARGET-30-PASXGP-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	61.36	neutral	PASXGP_01_TARGET
TARGET-30-PASXHE-01A-01D	TARGET-30-PASXHE-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	82.16	gain	PASXHE_01_TARGET
TARGET-30-PASXIE-01A-01D	TARGET-30-PASXIE-01A-01R	MYCN	Neuroblastoma	MYCN amp	3	1399.01	gain	PASXIE_01_TARGET
TARGET-30-PASXRG-01A-01D	TARGET-30-PASXRG-01A-01R	MYCN	Ganglioneuroblastoma	MYCN amp	14	306.49	amplification	PASXRG_01_TARGET
TARGET-30-PASXRJ-01A-01D	TARGET-30-PASXRJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	40.16	neutral	PASXRJ_01_TARGET
TARGET-30-PASYPX-01A-01D	TARGET-30-PASYPX-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	35.42	neutral	PASYPX_01_TARGET
TARGET-30-PASZPI-01A-01D	TARGET-30-PASZPI-01A-01R	MYCN	Neuroblastoma	MYCN amp	44	1114.27	amplification	PASZPI_01_TARGET
TARGET-30-PATBMM-01A-01D	TARGET-30-PATBMM-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	18.62	loss	PATBMM_01_TARGET
TARGET-30-PATCFL-01A-01D	TARGET-30-PATCFL-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	7.7	neutral	PATCFL_01_TARGET
TARGET-30-PATDWN-01A-01D	TARGET-30-PATDWN-01A-01R	MYCN	Neuroblastoma	MYCN amp	238	1794.12	amplification	PATDWN_01_TARGET
TARGET-30-PATDXC-01A-01D	TARGET-30-PATDXC-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	66.34	neutral	PATDXC_01_TARGET
TARGET-30-PATDXG-01A-01D	TARGET-30-PATDXG-01A-01R	MYCN	Neuroblastoma	MYCN amp	118	1668.97	amplification	PATDXG_01_TARGET
TARGET-30-PATEKG-01A-01D	TARGET-30-PATEKG-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	6.18	neutral	PATEKG_01_TARGET
TARGET-30-PATEPF-01A-01D	TARGET-30-PATEPF-01A-01R	MYCN	Ganglioneuroblastoma	MYCN non-amp	2	48.17	neutral	PATEPF_01_TARGET
TARGET-30-PATESI-01A-01D	TARGET-30-PATESI-01A-01R	MYCN	Neuroblastoma	MYCN amp	105	1468	amplification	PATESI_01_TARGET
TARGET-30-PATFCY-01A-01D	TARGET-30-PATFCY-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	73.78	loss	PATFCY_01_TARGET
TARGET-30-PATFXV-01A-01D	TARGET-30-PATFXV-01A-01R	MYCN	Neuroblastoma	MYCN amp	188	1768.19	amplification	PATFXV_01_TARGET
TARGET-30-PATGLU-01A-01D	TARGET-30-PATGLU-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	3	56.8	gain	PATGLU_01_TARGET
TARGET-30-PATHVK-01A-01D	TARGET-30-PATHVK-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	4	29.58	neutral	PATHVK_01_TARGET
TARGET-30-PATINJ-01A-01D	TARGET-30-PATINJ-01A-01R	MYCN	Neuroblastoma	MYCN non-amp	2	64.06	neutral	PATINJ_01_TARGET
